Harpoon Therapy Inc. (HARP)
(Delayed Data from NSDQ)
$10.59 USD
-0.41 (-3.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $10.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.59 USD
-0.41 (-3.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $10.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
CannTrust (CTST) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During CannTrust's (CTST) fourth-quarter earnings call, investor focus will be on the updates pertaining to the company's default status reports and completion of its remediation activities.
What's in Store for Axsome (AXSM) This Earnings Season?
by Zacks Equity Research
On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?
by Zacks Equity Research
During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.
Onconova (ONTX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.
Harpoon Therapeutics, Inc. (HARP) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Harpoon Therapeutics, Inc. (HARP).